沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效观察
Curative effect of the GP combined with thalidomide in the treatment of advanced triple-negative breast cancer
-
摘要: 目的:探讨沙利度胺联合GP方案治疗晚期三阴性乳腺癌的临床疗效及不良反应。方法:对58例晚期三阴性乳腺癌随机分为沙利度胺联合GP方案组(联合组)和GP方案组(化疗组),比较2组的疗效、不良反应、肿瘤标志物及病人生存时间。结果:联合组有效率58.62%,高于化疗组的31.03%(P<0.05),中位生存时间37个月,长于化疗组的32个月(P<0.05);肿瘤标志物下降率65.51%,高于化疗组的37.93%(P<0.05);胃肠道反应率13.79%,低于化疗组的41.38%(P<0.05)。2组骨髓抑制、便秘的发生率差异均无统计学意义(P>0.05),其余不良反应不明显。结论:沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效肯定,不良反应轻,值得临床进一步推广。Abstract: Objective:To explore the curative effects and adverse reactions of GP combined with thalidomide in the treatment of advanced triple-negative breast cancer.Methods:A total of 58 patients with advanced triple-negative breast cancer were randomly divided into the GP combined with thalidomide group(combination group) and GP group(chemotherapy group)(29 cases each group).The curative effect,adverse reaction,tumor marker and median survival time(MST) between two groups were compared.Results:The effective rate in combination group(58.62%) was higher than that in chemothreapy group(31.03%)(P<0.05).The MST in combination group(37 months) was higher than that in chemothreapy group(32 months)(P<0.05).The decline rate of tumor markers in combination group(65.51%) was higher than that in chemothreapy group(37.93%)(P<0.05).The gastrointestinal reaction rate in combination group(13.79%) was lower than that in chemothreapy group(41.38%)(P<0.05).The difference of the incidence rates of the bone marrow depression and constipation between two groups were not statistically significant(P>0.05),other adverse rections were not obvious.Conclusions:GP combined with thalidomide in treating advanced triple-negative breast cancer is good curative effect and mild adverse reactions,which is worthy of promotion.
-
Key words:
- breast neoplasms /
- thalidomide /
- gemcitabine /
- cisplatin
-
[1] BEIKI O,HALL P,EKBOM A,et al.Breast cancer incidence and case fatality among 4.7million women in relation to social and ethnic background:a population-based cohort study[J].Breast Cancer Res,2012,14(1):R5. [2] 林志豪,金贞姬.沙利度胺治疗恶性肿瘤的研究进展[J].中国药业,2013,22(21):1. [3] ARMOIRY X,FAGNANI F,BENBOUBKER L,et al.Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs:a multi-centre retrospective cohort study[J]. J Clin Pharm Ther,2011,36(1):19. [4] 孙燕,周际昌.临床肿瘤内科手册[M].4版,北京:人民卫生出版社,2004:44. [5] NAVRATIL J,FABIAN P,PALACOVA M,et al.Triple negative breast cancer[J].Klin Onkol,2015,28(6):405. [6] PRAT A,ADAMO B,CHEANG MC,et al.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer[J].Oncologist,2013,18(2):123. [7] 管小青,顾书成,郑向欣,等.TNBC的新辅助化疗:附31例报告[J].中国普通外科杂志,2014,23(11):1527. [8] WU J,LI S,JIA W,et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J].J Cancer Res Clin Oncol,2011,137(10):1505. [9] GHERSI D,WILLSON ML,CHAN MM,et al.Taxane-containing regimens for metastatic breast cancer[J].Cochrane Database Syst Rev,2015,6(10):3366. [10] WU K,YANG Q,LIU Y,et al.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy[J].World J Surg Oncol,2014,12(95):1219. [11] 谢娜,彭晔,王美芹,等.沙利度胺联合化学治疗肺癌临床研究进展[J].医学导报,2014,33(8):1059. [12] 昝瑛,张寅斌,王西京,等.沙利度胺联合铂类方案治疗三阴性乳腺癌肝转移[J].现代肿瘤医学,2014,22(11):2626. [13] 梁万霞,顾康生.沙利度胺联合DOF方案与单纯DOF方案一线治疗晚期胃癌的疗效观察[J].肿瘤防治研究,2015,42(3):278. [14] 马守成,乔慧,杨天宁,等.沙利度胺联合GP方案治疗晚期乳腺癌的疗效分析[J].肿瘤学杂志,2016,22(6):519. [15] 左彩莹.沙利度胺联合盐酸托烷司琼对转移性乳腺癌GP方案化疗所致的恶心、呕吐的疗效观察[J].肿瘤临床研究,2014,27(12):1491.
计量
- 文章访问数: 3833
- HTML全文浏览量: 582
- PDF下载量: 79
- 被引次数: 0